Assessing the risk of breast cancer.

Each year in the United States, breast cancer is diagnosed in more than 170,000 women.1 Despite this substantial burden of disease, however, assessment of breast-cancer risk has received very little attention outside the oncology clinic.2,3 In primary care, the main result of the recognition of individual variation in breast-cancer risk is the use of age to determine recommendations regarding mammography (older age is a strong risk factor for breast cancer).4 Recent developments in the ability to predict and alter breast-cancer risk warrant a new look at the role of assessment of this risk in primary care. Physicians must become . . .

[1]  J Benichou,et al.  Proportion of breast cancer cases in the United States explained by well-established risk factors. , 1995, Journal of the National Cancer Institute.

[2]  M. Somerfield,et al.  American Society of Clinical Oncology technology assessment on breast cancer risk reduction strategies: tamoxifen and raloxifene. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  D. Eddy Screening for breast cancer. , 1989, Annals of internal medicine.

[4]  M. Badzioch,et al.  RISK OF FAMILIAL BREAST CANCER , 1984, The Lancet.

[5]  P. Ganz,et al.  Agreement between breast cancer risk estimation methods. , 1996, Journal of the National Cancer Institute.

[6]  Cancer families: what risks are they given and do the risks affect management? , 1996, Journal of medical genetics.

[7]  M. Gail,et al.  Risk-based recommendations for mammographic screening for women in their forties. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  K. Offit,et al.  Quantitating familial cancer risk: a resource for clinical oncologists. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  D J Schaid,et al.  Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer. , 1999, The New England journal of medicine.

[10]  W D Dupont,et al.  Risk factors for breast cancer in women with proliferative breast disease. , 1985, The New England journal of medicine.

[11]  E. Lustbader,et al.  Validation of a breast cancer risk assessment model in women with a positive family history. , 1994, Journal of the National Cancer Institute.

[12]  F. Speizer,et al.  Cohort studies of fat intake and the risk of breast cancer--a pooled analysis. , 1996, The New England journal of medicine.

[13]  M. King,et al.  PRACTICAL GUIDE FOR ESTIMATING RISK FOR FAMILIAL BREAST CANCER , 1983, The Lancet.

[14]  C A Kelsey,et al.  Benefits versus risks from mammography: A critical reasessment , 1996, Cancer.

[15]  R. Shore,et al.  The risk of breast cancer after irradiation of the thymus in infancy. , 1989, The New England journal of medicine.

[16]  S. Pauker,et al.  Individualizing therapy to prevent long-term consequences of estrogen deficiency in postmenopausal women. , 1999, Archives of internal medicine.

[17]  J. Freudenheim,et al.  Lactation history and breast cancer risk. , 1997, American journal of epidemiology.

[18]  K M Kuntz,et al.  Decision analysis--effects of prophylactic mastectomy and oophorectomy on life expectancy among women with BRCA1 or BRCA2 mutations. , 1997, The New England journal of medicine.

[19]  Caroline S. Fox,et al.  Hormone Therapy To Prevent Disease and Prolong Life in Postmenopausal Women , 1992, Annals of Internal Medicine.

[20]  D. Bentley,et al.  Identification of the breast cancer susceptibility gene BRCA2 , 1995, Nature.

[21]  F. Speizer,et al.  Alcohol and breast cancer in women: a pooled analysis of cohort studies. , 1998, JAMA.

[22]  P. Rowe ACS orders mammography for younger women , 1997, The Lancet.

[23]  D Spiegelman,et al.  Validation of the Gail et al. model for predicting individual breast cancer risk. , 1994, Journal of the National Cancer Institute.

[24]  T. Sellers,et al.  Hormonal replacement therapy and morbidity and mortality in a prospective study of postmenopausal women. , 1995, American journal of public health.

[25]  Lisa M. Schwartz,et al.  The Role of Numeracy in Understanding the Benefit of Screening Mammography , 1997, Annals of Internal Medicine.

[26]  S. Shapiro,et al.  Case-control study of oral contraceptive use and risk of breast cancer. , 1996, American journal of epidemiology.

[27]  J Benichou,et al.  Validation studies for models projecting the risk of invasive and total breast cancer incidence. , 1999, Journal of the National Cancer Institute.

[28]  C K Redmond,et al.  Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. , 1999, Journal of the National Cancer Institute.

[29]  Graham A. Colditz,et al.  Risk factors for breast cancer according to family history of breast cancer , 1996 .

[30]  Postmenopausal hormone therapy and mortality. , 1997 .

[31]  M. Gail,et al.  Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. , 1989, Journal of the National Cancer Institute.

[32]  M. Stefanek Bilateral prophylactic mastectomy: issues and concerns. , 1995, Journal of the National Cancer Institute. Monographs.

[33]  Kristin Anderson,et al.  The Role of Hormone Replacement Therapy in the Risk for Breast Cancer and Total Mortality in Women with a Family History of Breast Cancer , 1997, Annals of Internal Medicine.

[34]  S. Cummings,et al.  The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. , 1999, JAMA.

[35]  R. Hendrick,et al.  Benefit of screening mammography in women aged 40-49: a new meta-analysis of randomized controlled trials. , 1997, Journal of the National Cancer Institute. Monographs.

[36]  J Chang-Claude,et al.  Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. , 1998, American journal of human genetics.

[37]  G A Colditz,et al.  The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. , 1995, The New England journal of medicine.

[38]  N. Risch,et al.  Autosomal dominant inheritance of early‐onset breast cancer. Implications for risk prediction , 1994 .

[39]  D. Easton,et al.  Estimates of the gene frequency of BRCA1 and its contribution to breast and ovarian cancer incidence. , 1995, American journal of human genetics.

[40]  P. Hartge,et al.  The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. , 1997, The New England journal of medicine.

[41]  W D Flanders,et al.  The lifetime risk of developing breast cancer. , 1993, Journal of the National Cancer Institute.

[42]  R. Thompson,et al.  Revisions in the risk‐based breast cancer screening program at group health cooperative , 1990, Cancer.

[43]  C. Weinberg,et al.  Population attributable fraction estimation for established breast cancer risk factors: considering the issues of high prevalence and unmodifiability. , 1998, American journal of epidemiology.

[44]  C. Christiansen,et al.  Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. , 1997, The New England journal of medicine.

[45]  F. Couch,et al.  BRCA1 mutations in women attending clinics that evaluate the risk of breast cancer. , 1997, The New England journal of medicine.

[46]  W. Chow,et al.  Underreporting and Misclassification of Urinary Tract Cancer Cases on Death Certificates , 1996, Epidemiology.

[47]  Steven E. Bayer,et al.  A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. , 1994, Science.

[48]  T. Powles,et al.  Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial , 1998, The Lancet.

[49]  P. Boyle,et al.  Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomised trial among hysterectomised women , 1998, The Lancet.

[50]  D P Byar,et al.  Estimating the population attributable risk for multiple risk factors using case-control data. , 1985, American journal of epidemiology.

[51]  K. Kerlikowske,et al.  Cost-Effectiveness of Extending Screening Mammography Guidelines To Include Women 40 to 49 Years of Age , 1997, Annals of Internal Medicine.